Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Methocarbamol
Drug ID BADD_D01415
Description Methocarbamol was developed in the early 1950s as a treatment for muscle spasticity and the associated pain.[A178441,A178450] It is a guaiacol glyceryl ether.[A178450] Methocarbamol tablets and intramuscular injections are prescription medicines indicated in the United States as an adjunct to rest, physical therapy, and other measures for the relief of discomforts associated with acute, painful musculoskeletal conditions.[Label,L6268] In Canada, methocarbamol can be sold as an over the counter oral medicine at a lower dose that may be combined with [acetaminophen] or [ibuprofen].[L6295] A combination product with [acetylsalicylic acid] and [codeine] is available in Canada by prescription.[L6295] Methocarbamol was FDA approved on 16 July 1957.[L6265]
Indications and Usage Methocarbamol tablets and intramuscular injections are indicated in the United States as an adjunct to rest, physical therapy, and other measures for the relief of discomforts associated with acute, painful musculoskeletal conditions.[Label,L6268] Oral methocarbamol in America may be given up to 1500mg 4 times daily for 2-3 days.[A31312] In Canada, methocarbamol containing oral formulations are sold over the counter for pain associated with muscle spasm.[L6295] However, if these combination formulations include codeine, they are prescription only.[L6295]
Marketing Status approved; vet_approved
ATC Code M03BA03
DrugBank ID DB00423
KEGG ID D00402
MeSH ID D008721
PubChem ID 4107
TTD Drug ID D0FN7J
NDC Product Code 72789-110; 0904-7058; 49452-4575; 65072-0401; 66652-1000; 43547-405; 50090-5846; 60687-559; 60687-568; 63187-087; 63629-1123; 67296-1435; 71205-019; 71610-223; 80425-0283; 10695-096; 58343-0138; 31722-533; 35573-413; 45865-987; 50268-520; 53002-3042; 59651-341; 61919-610; 61919-903; 63187-019; 63629-2418; 63629-8995; 67296-1825; 69367-256; 69584-611; 0517-1825; 71205-097; 71205-285; 80425-0138; 12666-0003; 51927-2519; 62991-2895; 43547-226; 50090-5847; 51407-468; 60760-725; 61919-148; 63187-130; 63629-2419; 67296-1453; 0404-9992; 68071-2563; 68083-317; 68788-6391; 70069-101; 71610-242; 55154-2129; 55700-890; 60429-118; 63323-778; 63629-2417; 63629-2420; 68788-7973; 70868-910; 71335-0771; 76385-123; 83008-008; 38779-1943; 31722-534; 50090-5907; 55150-223; 55700-218; 61919-616; 61919-627; 71335-0828; 71335-0844; 71335-1795; 71610-599; 72189-284; 80425-0021; 52076-6206; 62207-952; 36000-302; 43598-839; 50090-4164; 51407-467; 51662-1435; 55700-990; 60429-119; 63629-1622; 68788-7809; 70518-3096; 71205-103; 71610-174; 72789-022; 0641-6217; 76420-258; 51552-1018; 10135-722; 58343-0128; 60592-428; 25021-675; 35356-887; 51655-575; 55154-2334; 55154-2335; 63629-1124; 67296-1049; 68475-002; 69584-612; 70518-3117; 71093-141; 71288-716; 72789-021; 0641-6103; 76385-124; 0904-7057; 50090-1781; 50090-3578; 50090-5008; 53002-3590; 55700-716; 68071-5222; 68788-7980; 71205-375; 0615-8436; 10135-723; 58343-0142; 35561-211; 45865-100; 50268-521; 55154-2130; 59088-724; 59651-340; 61919-368; 66267-803; 71093-140; 71335-0970; 71335-1727; 71610-598; 0615-8435; 72789-012; 80425-0171; 80425-0275; 35561-212; 35573-414; 50090-5005; 63629-9288; 69367-255; 70518-1554; 70868-901; 71335-0251; 72789-041; 76420-040; 80425-0020; 51655-574; 53002-3041; 0276-0510
UNII 125OD7737X
Synonyms Methocarbamol | Guaiphenesin Carbamate | Carbamate, Guaiphenesin | Parabaxin | Ortoton | Robaxin | Lumirelax
Chemical Information
Molecular Formula C11H15NO5
CAS Registry Number 532-03-6
SMILES COC1=CC=CC=C1OCC(COC(=O)N)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Sedation17.02.04.005--Not Available
Seizure17.12.03.001--
Shock24.06.02.002--Not Available
Somnolence19.02.05.003; 17.02.04.006--
Swelling face08.01.03.100; 23.04.01.018; 10.01.05.0180.000061%Not Available
Syncope02.11.04.015; 24.06.02.012; 17.02.04.008--
Throat tightness22.12.03.031; 19.01.02.0050.000061%Not Available
Thrombophlebitis24.01.02.001--Not Available
Tinnitus17.04.07.004; 04.04.01.002--
Urticaria23.04.02.001; 10.01.06.001--
Vertigo17.02.12.002; 04.04.01.003--
Vision blurred17.17.01.010; 06.02.06.007--
Vomiting07.01.07.0030.000135%
Mental status changes19.07.01.0010.000061%Not Available
Acute generalised exanthematous pustulosis12.03.01.005; 11.07.01.018; 10.01.01.034; 23.03.10.0020.000061%Not Available
Inadequate analgesia12.02.20.006; 08.06.01.0400.000208%Not Available
Therapeutic product effect incomplete08.06.01.052--Not Available
The 3th Page    First    Pre   3    Total 3 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene